Dermatomyositis and polymyositis (myositis) trials in China

In China 38 Also abroad 124

38 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Where
Hangzhou
Age
5 years and over
People
11
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07184450
Early phase 1Taking people
Safety Study of CC312 in Autoimmune Disease Patients
Where
Tianjin
Age
18 years and over
People
18
Run by
CytoCares Inc
See details and how to joinNCT06888960
No phaseTaking people
Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation
Where
Beijing
Age
18 years to 80 years
People
100
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07037472
Early phase 1Not yet taking people in China
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
Where
Beijing
Age
18 years to 70 years
People
12
Run by
Peking University People's Hospital
See details and how to joinNCT06986018
Phase 1Taking people
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
44
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06980597
Early phase 1Not yet taking people in China
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Where
Suzhou
Age
18 years and over
People
15
Run by
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT06970951
Phase 1Taking people
Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
Where
Guangzhou
Age
18 years to 75 years
People
10
Run by
Li Shiyue
See details and how to joinNCT06919380
Phase 1Taking people
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
Where
Hangzhou
Age
5 years and over
People
18
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06686524
Early phase 1Taking people
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Where
Wuhan
Age
18 years to 75 years
People
36
Run by
Tongji Hospital
See details and how to joinNCT04561557
Phase 1Taking people
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Where
Hangzhou
Age
5 years to 17 years
People
10
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06569472
Phase 4Enrolling by invitation
3T Therapy in the Treatment of MDA5-positive Dermatomyositis
Where
Hangzhou
Age
18 years and over
People
133
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06438679
No phaseTaking people
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
Where
Beijing, Changsha, Chongqing, Hangzhou, Nanjing, Shenzhen
Age
Up to 18 years
People
20,000
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06417502
No phaseTaking people
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
Where
Beijing
Age
18 years to 100 years
People
50
Run by
Chinese PLA General Hospital
See details and how to joinNCT06203249